How does 0FIW's PE Ratio compare to its peers?

0FIW is expensive based on its Price-To-Earnings Ratio (31.3x) compared to the peer average (30.9x).

How does 0FIW's PE Ratio compare vs other companies in the European Medical Equipment Industry?

0FIW is expensive based on its Price-To-Earnings Ratio (31.3x) compared to the European Medical Equipment industry average (29.7x).

What is 0FIW's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 0FIW's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of 0FIW when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

0FIW (DKK34.7) is trading below our estimate of [[fair value]] (DKK38.62)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is less than 20% higher than the current share price.

Embla Medical hf (LSE:0FIW) - Stock Price, News & Analysis

0FIW Stock Overview

Provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. More details

0FIW fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	3/6
Past Performance	4/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 10.1% below our estimate of its fair value

Earnings are forecast to grow 16.88% per year

Earnings have grown 6% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

Has a high level of debt

Embla Medical hf. Competitors

Smith & Nephew

LSE:SN.

UK£8.6b

NIOX Group

AIM:NIOX

UK£260.3m

EKF Diagnostics Holdings

AIM:EKF

UK£116.6m

ConvaTec Group

LSE:CTEC

UK£4.9b

Price History & Performance

Summary of all time highs, changes and price drops for Embla Medical hf
Historical stock prices
Current Share Price	DKK 34.70
52 Week High	DKK 35.90
52 Week Low	DKK 27.45
Beta	0.63
11 Month Change	16.05%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	-28.75%
Change since IPO	-80.38%

Recent updates

Shareholder Returns

	0FIW	GB Medical Equipment	GB Market
7D	0%	7.7%	-0.4%
1Y	n/a	-2.1%	5.6%

Return vs Industry: Insufficient data to determine how 0FIW performed against the UK Medical Equipment industry.

Return vs Market: Insufficient data to determine how 0FIW performed against the UK Market.

Price Volatility

Is 0FIW's price volatile compared to industry and market?
0FIW volatility
0FIW Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	6.1%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0FIW's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine 0FIW's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1971	4,000	Sveinn Solvason	www.emblamedical.com

Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics, Bracing & Supports, and Patient Care. The Prosthetics segment offers mechanical products, such as lower limb prosthetics and finger prostheses; and bionic products microprocessor-controlled feet, knees, hands, liners, fingers, and other components integrated.

Embla Medical hf. Fundamentals Summary

How do Embla Medical hf's earnings and revenue compare to its market cap?
0FIW fundamental statistics
Market cap	DKK 15.33b
Earnings (TTM)	DKK 489.38m
Revenue (TTM)	DKK 5.95b

31.3x

P/E Ratio

2.6x

P/S Ratio

Is 0FIW overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0FIW income statement (TTM)
Revenue	US$840.31m
Cost of Revenue	US$319.17m
Gross Profit	US$521.13m
Other Expenses	US$452.07m
Earnings	US$69.07m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 05, 2025

Earnings per share (EPS)	0.16
Gross Margin	62.02%
Net Profit Margin	8.22%
Debt/Equity Ratio	50.7%

How did 0FIW perform over the long term?

See historical performance and comparison

0FIW Stock Overview

Rewards

Risk Analysis

Embla Medical hf. Competitors

LSE:SN.

UK£8.6b

AIM:NIOX

UK£260.3m

AIM:EKF

UK£116.6m

LSE:CTEC

UK£4.9b

Price History & Performance

Recent News & Updates

Investor sentiment improves as stock rises 18%

Third quarter 2024 earnings released: EPS: US$0.051 (vs US$0.033 in 3Q 2023)

Less than half of directors are independent

Less than half of directors are independent

Embla Medical hf. Revises Earnings Guidance for the Full Year of 2024

Embla Medical hf. Revises Earnings Guidance for the Full Year of 2024

Recent updates

Investor sentiment improves as stock rises 18%

Third quarter 2024 earnings released: EPS: US$0.051 (vs US$0.033 in 3Q 2023)

Less than half of directors are independent

Less than half of directors are independent

Embla Medical hf. Revises Earnings Guidance for the Full Year of 2024

Embla Medical hf. Revises Earnings Guidance for the Full Year of 2024

Less than half of directors are independent

First quarter 2024 earnings released: EPS: US$0.019 (vs US$0.024 in 1Q 2023)

Less than half of directors are independent

Össur hf. Appoints Caroline Vagner Rosenstand to the Audit Committee

Less than half of directors are independent

Investor sentiment improves as stock rises 16%

Full year 2023 earnings released: EPS: US$0.14 (vs US$0.10 in FY 2022)

Össur hf. Provides Earnings Guidance for the Year 2024

Less than half of directors are independent

Össur hf. to Report Q1, 2024 Results on Apr 23, 2024

Össur hf., Annual General Meeting, Mar 12, 2025

Less than half of directors are independent

Össur hf. Reaffirms Financial Guidance for the Year 2023

Less than half of directors are independent

Össur hf. Announces Executive Changes

First quarter 2023 earnings released: EPS: US$0.024 (vs US$0.022 in 1Q 2022)

Less than half of directors are independent

Less than half of directors are independent

Össur hf. Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released

Less than half of directors are independent

Össur hf. to Report Q1, 2023 Results on Apr 25, 2023

Less than half of directors are independent

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: US$0.016 (vs US$0.041 in 3Q 2021)

Less than half of directors are independent

Össur hf. (CPSE:OSSR) acquired Naked Prosthetics.

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: US$0.034 (vs US$0.046 in 2Q 2021)

Össur hf. Revises Earnings Guidance for the Year 2022

Össur hf. Reports Preliminary Earnings Results for the Second Quarter and First Half of 2022

Less than half of directors are independent

Össur Appoints Gudny Arna Sveinsdottir as Chief Financial Officer, Effective September 1, 2022

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Össur Hf. Announces New R&D Leadership

Less than half of directors are independent

Össur Launches New POWER KNEE

Össur hf. Announces Sales Guidance for the Full Year 2022

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Össur Hf. Announces Earnings Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS US$0.027 (vs US$0.017 in 1Q 2020)

Össur Hf. Provides Financial Guidance for the Full Year 2021

Vice Chairman Kristján Ragnarsson has left the company

Full year 2020 earnings released: EPS US$0.015 (vs US$0.16 in FY 2019)

Revenue misses expectations

Össur hf., Annual General Meeting, Mar 08, 2022

Laboratoires Innothera S.A.S completed the acquisition of Gibaud SAS from Össur hf. (CPSE:OSSR).

Össur Hf. Withdraw Its Financial Guidance for 2020

Shareholder Returns